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Abstract: Targeting angiogenesis through inhibition of the vascular endothelial growth factor 
(VEGF) pathway has been successful in the treatment of late stage colorectal cancer. How-
ever, not all patients benefit from inhibition of VEGF. Ras status is a powerful biomarker for 
response to anti-epidermal growth factor receptor therapy; however, an appropriate biomarker for 
response to anti-VEGF therapy is yet to be identified. VEGF and its receptors, FLT1 and KDR, 
play a crucial role in colon cancer progression; individually, these factors have been shown to 
be prognostic in colon cancer; however, expression of none of these factors alone was predic-
tive of tumor response to anti-VEGF therapy. In the present study, we analyzed the expression 
levels of VEGFA, FLT1, and KDR in two independent colon cancer datasets and found that 
high expression levels of all three factors afforded a very poor prognosis. The observation was 
further confirmed in another independent colon cancer dataset, wherein high levels of expres-
sion of this three-gene signature was predictive of poor prognosis in patients with proficient 
mismatch repair a wild-type KRas status, or mutant p53 status. Most importantly, this signature 
also predicted tumor response to bevacizumab, an antibody targeting VEGFA, in a cohort of 
bevacizumab-treated patients. Since bevacizumab has been proven to be an important drug in 
the treatment of advanced stage colon cancer, our results suggest that the three-gene signature 
approach is valuable in terms of its prognostic value, and that it should be further evaluated in 
a prospective clinical trial to investigate its predictive value to anti-VEGF treatment.
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Introduction
Angiogenesis plays a critical role in the progression of colon cancer, and the vascular 
endothelial growth factor (VEGF) pathway has been shown to play a central role in 
controlling tumor angiogenesis.1 VEGF ligands, such as VEGFA, VEGFB, VEGFC, 
and VEGFD have different affinities toward, and activation potencies at, different 
VEGF receptors, including VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).2 
VEGFA has been shown to activate both FLT1 and KDR,2 and activation of this signal-
ing pathway has led to vascularization and angiogenesis in malignant tissue to support 
its growth and survival.3 VEGFA has been shown to be overexpressed in colorectal 
cancer specimens, especially in those tumors with secondary metastases, including 
liver or lymph node metastases.4–7 Its mRNA expression in tumor as well as plasma 
is higher in colorectal cancer patients than in non-diseased patients.8 Despite this, 
VEGF expression has not been shown to be predictive of response to bevacizumab.9 
In addition, VEGFA was shown to be a significant predictor for morbidity in a col-
orectal cancer cohort.10
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Expression of FLT1, also known as VEGFR1, was shown 
to be higher in primary tumors and nodal metastases of col-
orectal carcinomas, and its overexpression was associated with 
lymphovascular invasion and local disease recurrence, but not 
with survival.11 Moreover, the serum level of soluble FLT1 
has also been shown to be significantly higher in patients with 
colorectal cancer compared to non-diseased individuals.12 
Likewise, KDR, also known as VEGFR2, has been shown 
to be overexpressed in metastatic colon cancer.6 Overexpres-
sion of its phosphorylated version was associated with larger 
tumor diameter and poor histological differentiation,10 while 
several single nucleotide polymorphisms of KDR have also 
been identified that were postulated to modulate recurrence 
of colorectal cancer in patients receiving chemotherapy.13 
Further investigation on various angiogenic factors in a large 
colorectal cancer patient cohort has further suggested that 
the expression of angiogenic factors can be associated with 
tumors of more aggressive phenotypes.14
Inhibition of the VEGF pathway using antibodies, recom-
binant fusion proteins, or tyrosine kinase inhibitors has been 
shown to be a successful approach in prolonging survival of 
patients with stage IV colorectal cancer.15 Bevacizumab is a 
humanized monoclonal immunoglobulin G1 antibody against 
soluble VEGFA that has been shown to be an effective and 
tolerable therapy that improves survival in colorectal cancer 
patients.16 In a phase III trial (AVF2107g), patients with meta-
static colon cancer who received bevacizumab in addition to 
chemotherapy (irinotecan, bolus fluorouracil, and leucovorin) 
had significantly longer progression-free and overall surviv-
als than patients who received chemotherapy only.17 Another 
phase III trial has also confirmed the efficacy of bevacizumab 
in treatment of colorectal cancer.18 Recent advances in the 
targeting of angiogenesis in colorectal cancer include the 
approval of novel agents,19,20 the demonstration of the impor-
tance of continuous inhibition of the VEGF pathway,19,21,22 and 
the investigation of the efficacy and safety of bevacizumab 
in the elderly.23 While the success of anti-EGFR (epidermal 
growth factor receptor) antibody therapy in advanced stage 
colorectal cancer patients has been improved by selecting 
patients based on their NRas status in addition to their KRas 
status,24–26 no such predictive biomarker exists for improving 
the success of antibody targeting of angiogenesis.
The prognostic value of individual angiogenic factors in 
colorectal cancer has been limited; for more comprehensive 
prognostication, co-consideration of multiple angiogenic 
factors and receptors may be more valuable.5 The survival 
rate of colorectal cancer patients was shown to be poor 
when their tumor cells overexpressed VEGFA, and their 
tumor-associated endothelial cells overexpressed KDR.7 
Antiangiogenic therapy is also a successful strategy in the 
treatment of lung cancer patients;27,28 we recently reported 
that a VEGFA-FLT1-KDR gene signature had strong prog-
nostic significance in lung cancer patients.29 In the present 
study, we investigated the prognostic significance of the 
combined mRNA expressions of VEGFA, FLT1, and KDR 
in colorectal cancer using colon cancer datasets available in 
the Gene Expression Omnibus (GEO) database.
Materials and methods
Extraction of clinical and microarray 
gene expression data from colon cancer 
patient datasets
Three colorectal cancer patient datasets, GSE14333,30 
GSE14538,31 and GSE4096732 were identified in the GEO data-
base; datasets compiled using the HG-U133 microarray plat-
form, which comprised $200 patients for whom survival data 
were available in the GEO database were included in this study. 
A separate colorectal cancer patient cohort, GSE19862, which 
contained information on patient response to bevacizumab 
treatment, was also analyzed. Microarray gene expression data 
were retrieved from the data matrixes deposited to the GEO 
database by the original authors. R scripting was used to extract 
the expression values of a small number of genes (probesets) 
of interest, and the clinical data from the data matrixes were 
downloaded from GEO, as previously described.33
Correlations of gene expression levels 
and clinical data
All statistical analyses were performed using SPSS version 
19.0. Expression levels were divided into high and low levels 
using the median expression level as the cut-off point for 
Kaplan–Meier survival analysis. Results were compared by 
log-rank test. Univariate Cox regression analysis was used to 
correlate gene expression levels and patient survival. Patients 
were divided into three groups based on the expression levels 
of VEGFA and FLT1; the VEGFA-FLT1-low group consisted 
of patients who expressed both genes below median levels 
(low); the VEGFA-FLT1-high group consisted of patients 
who expressed both genes at above median levels (high); the 
VEGFA-FLT1-intermediate group consisted of the remaining 
patients, who expressed either gene at above median level, 
and the other below median. Similar stratification was per-
formed for the VEGFA-KDR grouping. Patients were also 
divided into four groups based on the expression levels of 
VEGFA, FLT1, and KDR depending on the number of genes 
expressed at above the median. The survival time of patients 
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stratified by this grouping method were analyzed by Kaplan–
Meier analysis and Cox regression.
Results
The association between mRNA 
expression of VEGFA, FLT1, and KDR,  
and colon cancer patient survival
A high level of expression of VEGFA in both GSE14333 
(P=0.052) and GSE17538 (P=0.006) was associated with 
poorer disease-free survival (Figure 1A and B). Similarly, a 
high level of expression of FLT1 (VEGFR1) was associated 
with poorer disease-free survival in both cohorts (P=0.016 for 
GSE14333 and P=0.075 for GSE17538; Figure 1C and D). 
However, the association between KDR (VEGFR2) expres-
sion and disease-free survival was less pronounced in these 
two datasets (Figure 1E and F).
The prognostic significance of VEGFA-
FLT1 and VEGFA-KDR combinations
The prognostic significance of VEGFA, FLT1, or KDR was 
not consistently significantly demonstrated in the two colon 
cancer datasets. In an attempt to boost their prognostic power, 
Figure 1 The association between VEGFA, FLT1, and KDR mrna expression and colon cancer patient survival.
Notes: Kaplan–Meier analyses for VEGFA mRNA expression in (A) GSE14333 and (B) GSE17538. Kaplan–Meier analyses for FLT1 mRNA expression in (C) GSE14333 and 
(D) GSE17538. Kaplan–Meier analyses for KDR mRNA expression in (E) GSE14333 and (F) GSE17538.
Abbreviation: VEGFA, vascular endothelial growth factor a.
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we assessed co-overexpression of the ligand, VEGFA, and its 
receptors, FLT1 or KDR. As expected, patients whose primary 
tumors expressed high levels of both VEGFA and FLT1 had a 
significantly poorer survival than patients who had low expres-
sion of both VEGFA and FLT1 in both colon cancer datasets 
(P=0.008 and P=0.004, respectively; comparison for all three 
groups, P=0.004 and P=0.026, respectively, for GSE14333 
and GSE17538; Figure 2A and B). Similarly, patients whose 
primary tumors expressed high levels of both VEGFA and 
KDR had a significantly poorer survival than patients who had 
low expression of both VEGFA and KDR in both colon cancer 
datasets (P=0.011 and P=0.001, respectively; comparison 
for all three groups, P=0.053 and P=0.008, respectively, for 
GSE14333 and GSE17538; Figure 2C and D).
The prognostic significance of the  
VEGFA-FLT1-KDR combination
Since the combinations of VEGFA-FLT1 and VEGFA-KDR 
were shown to be more consistent in terms of prognostication 
than when these genes were considered individually, we 
further investigated whether combination assessment of 
expression of the three genes, VEGFA-FLT1-KDR, could 
be a better prognostic indicator. In GSE14333, patients 
whose tumors expressed all three genes at a low level had a 
mean disease-free survival of 101 months (95% confidence 
interval [CI] =86–116 months), which is significantly longer 
than patients whose tumors expressed all three genes at a 
high level (mean disease-free survival =72 months, 95% 
CI =54–90 months). As shown in Figure 3A, the VEGFA-
FLT1-KDR gene signature was significantly associated with 
disease-free survival in colon cancer patients (P=0.014). 
Similar results were obtained using the GSE17538 dataset. 
Patients whose tumors expressed all three genes at a low level 
had a mean disease-free survival of 104 months (95% CI = 
95–113 months), while those who expressed all three genes 
at a high level had a mean disease-free survival of 71 months 
(95% CI =57–86 months). As shown in Figure 3B, the 
VEGFA-FLT1-KDR gene signature was again significantly 
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Figure 2 The association between combination of VEGFA/FLT1 and VEGFA-KDR mrna expression and colon cancer patient survival.
Notes: Kaplan–Meier analyses for VEGFA and FLT1 mRNA expression in combination in (A) GSE14333 and (B) GSE17538. Kaplan–Meier analyses for VEGFA and KDR mrna 
expression in combination in (C) GSE14333 and (D) GSE17538.
Abbreviation: VEGFA, vascular endothelial growth factor a.
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Figure 3 The association between the combination of VEGFA/FLT1/KDR mrna 
expression and colon cancer patient survival.
Notes: Kaplan–Meier analyses for VEGFA, FLT1, and KDR mrna expression in 
combination in (A) GSE14333 and (B) GSE17538.
Abbreviation: VEGFA, vascular endothelial growth factor a.
Table 1 Patient clinical and pathologic features for GSE40967
Number  
of cases
Percent Median 
(range)
age 565 68.1 (22–97) 
years
stage
0 4 0.7
1 33 5.8
2 264 46.6
3 205 36.2
4 60 10.6
sex
Female 256 45.2
Male 310 54.8
location
Proximal 224 39.6
Distal 342 60.4
Colon cancer subtype
C1 (chromosome instability– 
immune-down subtype)
116 20.5
C2 (dMMR subtype) 104 18.4
C3 (KRas mutant subtype) 75 13.3
C4 (cancer stem cell subtype) 59 10.4
C5 (chromosome instability– 
Wnt-up subtype)
152 26.9
C6 (chromosome instability– 
normal-like subtype)
60 10.6
MMr status
Proficient 444 78.4
Deficient 75 13.3
Missing 47 8.3
BRaf status
Wild-type 461 81.4
Mutant 51 9
Missing 54 9.5
Kras status
Wild-type 328 58
Mutant 217 38.3
Missing 21 3.7
p53 status
Wild-type 161 28.4
Mutant 190 33.6
Missing 215 38
Abbreviations: MMR, mismatch repair; dMMR, deficient mismatch repair.
associated with disease-free survival in this patient cohort 
(P=0.024).
The impact of genetic alterations on the 
prognostic significance of the VEGFA-
FLT1-KDR combination
In another independent dataset, GSE40967, which has 
available clinicopathological parameters, we sought to 
investigate whether the association between the three-gene 
signature and disease-free survival retained relevance in 
patients with specific genetic alterations. The clinical char-
acteristics for patients in this cohort are listed in Table 1. In 
the GSE40967 colon cancer patient cohort, patients whose 
tumors had a high level of expression of the three-gene 
signature again had a significantly shorter disease-free sur-
vival than those patients whose tumors had a low level of 
expression of the three-gene signature (P=0.048; Figure 4A). 
Interestingly, this VEGFA-FLT1-KDR signature and survival 
association was only significant in patients with proficient 
mismatch repair (MMR) status (P=0.031; Figure 4B), but 
not in those with deficient MMR status (P=0.657; data not 
shown). Likewise, the three-gene signature was a potent 
prognostic indicator in patients with wild-type KRas status 
(P=0.001; Figure 4C), but not in those with mutant KRas 
status (P=0.848; data not shown). Similarly, the three-gene 
signature was also significantly associated with survival in 
patients with mutant p53 status (P=0.038; Figure 4D), but 
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not in those with wild-type p53 status (P=0.501; data not 
shown).
The predictive value of the three-gene 
signature to treatment of bevacizumab
The ability of the three-gene signature to predict response to 
bevacizumab was tested in a cohort of colon cancer patients 
who had received bevacizumab treatment and for whom data 
regarding response to the therapy were known. We found 
that none of the patients who responded well to bevacizumab 
expressed the three-gene signature at a low level, while 
71% of those patients who did not respond to bevacizumab 
expressed the three-gene signature at a low level; however 
only 14% of patients who did not respond to bevacizumab 
expressed this three-gene signature at a low level (chi-square 
test, P=0.02; Figure 5).
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Figure 4 The association between the combination of VEGFA-FLT1-KDR mRNA expression and colon cancer patient survival in cohorts stratified based on genetic 
aberration.
Notes: Kaplan–Meier analyses for VEGFA, FLT1, and KDR mRNA expression in combination in GSE40967 in (A) the whole cohort, (B) patients with proficient mismatch 
repair, (C) patients with wild-type KRas status, and (D) patients with mutant p53 status.
Abbreviations: VEGFA, vascular endothelial growth factor a; mRNA, messenger ribonucleic acid; pMMR, proficient mismatch repair.
Discussion
Anti-angiogenic agents, such as bevacizumab, aflibercept, 
and regorafenib play an important role in the treatment of 
colon cancer. Importantly, continuous inhibition of the VEGF 
pathway has been shown to prolong survival in colon cancer 
patients,19–21 further reinforcing angiogenesis as an essential 
process in tumor progression and validating angiogenesis as 
an appropriate target for cancer therapy. Recent advances in 
molecular testing have led to the identification of a subgroup 
of patients, whose tumors have KRas or NRas mutations, 
for whom anti-EGFR antibodies, including cetuximab and 
panitumumab, are not a viable treatment option.24,34 However, 
no advances to identify suitable (or unsuitable) candidates 
for anti-angiogenesis treatment have been made. Our previ-
ous report showed that combining VEGFA, FLT1, and KDR 
expression could be a better prognostic indicator in lung 
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Figure 5 The association between the combination of VEGFA-FLT1-KDR mrna 
expression and response to bevacizumab in colon cancer patients in the GSE19862 
dataset.
Abbreviation: VEGFA, vascular endothelial growth factor a.
cancer compared to when these factors were considered 
individually.29 In the present study, we have shown that using 
similar methodology, this three-gene signature is a robust 
prognostic indicator in colon cancer. Most importantly, this 
three-gene signature has been shown to predict the response 
to bevacizumab, an anti-angiogenic agent. Since VEGFA 
activates both FLT1 and KDR,2 the co-overexpression of the 
ligand and the two receptors may be required for the activa-
tion of the pathway. In addition, as shown in Figure 3, the 
consideration of all three genes together can better stratify 
patients into smaller groups with a better defined prognosis, 
such that patients with all three genes expressed at high levels 
had the poorest prognosis compared to those with all three 
genes expressed at a low level, who had the best prognosis. 
Our results warrant further study on combining VEGFA, 
FLT1, and KDR expression profiling as a tool for predicting 
of response to anti-angiogenic agents in colorectal cancer 
patients. Since patient treatment was heterogeneous in the 
patient cohorts investigated in the present study, a prospec-
tive clinical trial is needed to test the clinical applicability 
for the three-gene signature as a prognostic and predictive 
biomarker for colorectal cancer patients.
Our results on the impact of genetic background on the 
prognostic significance of this three-gene signature for colon 
cancer are interesting and should be further investigated. 
MMR deficiency is an important prognostic determinant for 
colon cancer.35 A recent study has shown that bevacizumab 
may impose different effects on patients with MMR-deficient 
tumors compared to MMR-proficient tumors;36 in the current 
study, we show that the three-gene signature significantly 
predicted survival in patients with tumors proficient in MMR, 
but not in those with tumors deficient in MMR.
KRas status is an important biomarker for anti-EGFR 
therapy; however, it failed to offer predictive value for the 
anti-angiogenic agent, bevacizumab.37 As anti-EGFR agents 
are ineffective in colon cancers bearing KRas mutations, 
anti-angiogenic agents are the most common treatment option 
for this type of patients. In the present study, we found that 
the three-gene signature was highly prognostic in patients 
with wild-type KRas, but not in those with KRas mutation. 
Bevacizumab and cetuximab have both been shown to have 
similar efficacy in patients with KRas wild-type tumors in 
terms of response rate, progression-free survival, and overall 
survival,38–40 suggesting both anti-VEGF or anti-EGFR are 
viable options for colon cancer patients with wild-type KRas. 
The three-gene signature, when verified in a prospective trial, 
may be able to further stratify colon cancer patients with 
wild-type KRas in the future.
Previous reports investigating the association between 
mutational status of p53 and response to bevacizumab were 
contradictory; some reports showed that p53 status did not 
affect the efficacy of bevacizumab,41,42 while one report 
showed that patients with p53-positive (expression) tumors 
had a significantly longer survival when treated with beva-
cizumab with chemotherapy;43 another report showed that 
the progression-free survival was significantly longer with 
bevacizumab-containing regimens in patients with mutant 
p53 tumors, but not in those with wild-type p53 tumors.44 
In the present study, our results show that the three-gene 
signature is prognostic only in tumors with mutant p53, but 
not in those with wild-type p53, suggesting that VEGFA-
mediated angiogenesis may play an important role in a p53 
mutant genetic background. Further analysis is required to 
confirm the prognostic and predictive value of p53 in colon 
cancers treated with bevacizumab.
Conclusion
In conclusion, our results suggest that the three-gene sig-
nature may be a potential prognostic indictor for colon 
cancer and a potential predictive biomarker for response to 
anti-angiogenic agents such as bevacizumab. Importantly, 
the prognostic significance of this three-gene signature 
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has also been demonstrated in lung cancer, in which the 
efficacy of anti-angiogenic agents has been shown. Since 
anti-angiogenic agents have been shown to be active also in 
other cancer types, further investigation into the prognostic 
significance of this three-gene signature in other types of 
cancer is warranted.
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